Background:Lipocalins form a protein family with great functional similarities. Specifically, they absorb hydrophobic ligands, often complexed with iron, into their molecular pocket, and thereby act bacteriostatic. Accordingly, human lipocalin-2 (LCN2) is an acute phase protein involved in immune defense. Allergics harbor significantly lower LCN2 levels
1, in parallel they suffer from intracellular micronutritional deficiencies, especially of iron
2.
Aim:To study:
- whether the loading of lipocalins may determine why some animal lipocalins act as allergens, and
- whether loaded ligands may turn lipocalins tolerogenic.
Results:The lipocalin beta-lactoglobulin (BLG), best known from cow´s milk, acted as allergen only in its empty form
3,4. However, BLG complexed with ligands occurred in cow stable dust and contributed to the allergy protective effect of farms
5. We developed a lozenge using BLG as a Trojan horse to carry micronutrients to immune cells of allergics. In clinical double-blind placebo-controlled
6 and provocation trials in pollen and house dust mite allergics we demonstrated that with the BLG lozenge micronutritional deficiencies can be corrected. This is associated with a significant symptom relief.
Conclusion:We propose that spiking of lipocalins with nutrients, as shown for BLG, is a novel approach exploiting targeted micronutrition to halt the allergy epidemic.
E. Jensen-Jarolim is the inventor on “LCN2 as a tool for allergy diagnostic and therapy” (EP 14150965.3, Year: 01/2014; US 14/204,570) and shareholder of Biomedical Int. R+D GmbH, Vienna, Austria.